Italept

Levetiracetam, the active ingredient in Italept, is an anticonvulsant presented as an oral tablet for oral use. It is indicated for the treatment of partial, generalized tonic‑clonic and myoclonic seizures in patients diagnosed with epilepsy, helping to reduce seizure frequency and improve disease management. The product complies with EU regulatory standards and is manufactured under strict quality controls.

GNH USA supplies Italept as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable access to quality‑assured medication for epilepsy care.

Levetiracetam is used to control seizure activity across several epilepsy syndromes.

- Partial seizures: reduces frequency and severity of focal onset seizures, improving daily functioning in patients with epilepsy. - Generalized tonic‑clonic seizures: helps prevent bilateral convulsive episodes, decreasing risk of injury and hospitalization. - Myoclonic seizures: decreases rapid jerking movements, contributing to better control of seizure activity in myoclonic epilepsy.

Levetiracetam may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Dizziness - Fatigue - Somnolence - Headache

Serious or Rare Side Effects: - Severe skin reactions such as Stevens‑Johnson syndrome - Mood changes including depression or suicidal ideation - Blood disorders such as neutropenia

When prescribing or using Italept, several precautionary measures should be considered.

- Renal impairment: assess renal function and consider dose adjustment. - Hepatic impairment: monitor liver enzymes and adjust therapy if needed. - Pregnancy: discuss potential risks with prescriber; benefits may outweigh risks. - Concomitant CNS depressants: monitor for enhanced sedation or respiratory depression. - Psychiatric history: observe for mood alterations or behavioral changes. - Store at ambient temperature: keep in original container, protect from moisture and light.

Levetiracetam can interact with other medications, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Carbamazepine: may significantly reduce levetiracetam plasma concentrations. - Phenytoin: can lower levetiracetam levels, reducing efficacy. - Phenobarbital: may decrease levetiracetam exposure.

Moderate Interactions (Monitor Closely): - Valproic acid: may increase levetiracetam concentrations, requiring monitoring. - Topiramate: additive CNS depressant effects may occur. - Alcohol: can enhance sedation and dizziness.